Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

Science and technology consortia in U.S. biomedical research: a paradigm shift in response to unsustainable academic growth.

Balch C, Arias-Pulido H, Banerjee S, Lancaster AK, Clark KB, Perilstein M, Hawkins B, Rhodes J, Sliz P, Wilkins J, Chittenden TW.

Bioessays. 2015 Feb;37(2):119-22. doi: 10.1002/bies.201400167. Epub 2014 Nov 12. No abstract available.

PMID:
25387399
2.

Oxygen regulates molecular mechanisms of cancer progression and metastasis.

Gupta K, Madan E, Sayyid M, Arias-Pulido H, Moreno E, Kuppusamy P, Gogna R.

Cancer Metastasis Rev. 2014 Mar;33(1):183-215. doi: 10.1007/s10555-013-9464-2. Review.

PMID:
24338006
3.

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, Spafford MJ, Jones DV, Chung CH.

Oral Oncol. 2013 May;49(5):461-7. doi: 10.1016/j.oraloncology.2012.12.016. Epub 2013 Feb 4.

4.

A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.

Bauman JE, Eaton KD, Wallace SG, Carr LL, Lee SJ, Jones DV, Arias-Pulido H, Cerilli LA, Martins RG.

BMC Cancer. 2012 Oct 3;12:449. doi: 10.1186/1471-2407-12-449.

5.

Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.

Arias-Pulido H, Chaher N, Gong Y, Qualls C, Vargas J, Royce M.

BMC Cancer. 2012 Jul 19;12:298. doi: 10.1186/1471-2407-12-298.

6.

DR6 as a diagnostic and predictive biomarker in adult sarcoma.

Yang K, Mooney C, Spahlinger G, Schuetze S, Arias-Pulido H, Verschraegen C, Gimotty P, Buckanovich RJ.

PLoS One. 2012;7(5):e36525. doi: 10.1371/journal.pone.0036525. Epub 2012 May 2.

7.

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

Verschraegen CF, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, Schmit B, Quinn R, Muller CY, Rabinowitz I, Purdy M, Snyder D, Bocklage T.

Ann Oncol. 2012 Mar;23(3):785-90. doi: 10.1093/annonc/mdr299. Epub 2011 Jul 11.

8.

Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms.

Glass JP, Parasher G, Arias-Pulido H, Donohue R, Prossnitz ER, Cerilli LA.

Int J Surg Pathol. 2011 Oct;19(5):588-96. doi: 10.1177/1066896911409575. Epub 2011 Jun 1. Erratum in: Int J Surg Pathol. 2012 Apr;20(2):211.

PMID:
21632639
9.

Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients.

Chaher N, Arias-Pulido H, Terki N, Qualls C, Bouzid K, Verschraegen C, Wallace AM, Royce M.

Breast Cancer Res Treat. 2012 Jan;131(2):437-44. doi: 10.1007/s10549-011-1422-5. Epub 2011 Mar 1.

10.

Epidermal growth factor receptor as a biomarker for cervical cancer.

Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C.

Ann Oncol. 2011 Oct;22(10):2166-78. doi: 10.1093/annonc/mdq723. Epub 2011 Feb 16. Review.

11.

Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma.

Huang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, Prossnitz ER, Goldberg GL, Smith HO.

Am J Obstet Gynecol. 2010 Sep;203(3):242.e1-5. doi: 10.1016/j.ajog.2010.04.046. Epub 2010 Jun 3.

12.

Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.

Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB.

Clin Cancer Res. 2010 Jun 1;16(11):2999-3010. doi: 10.1158/1078-0432.CCR-09-3233. Epub 2010 Apr 19.

13.

GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.

Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M.

Breast Cancer Res Treat. 2010 Aug;123(1):51-8. doi: 10.1007/s10549-009-0631-7. Epub 2009 Nov 10.

14.

Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer.

Narayan G, Scotto L, Neelakantan V, Kottoor SH, Wong AH, Loke SL, Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A, Arias-Pulido H, Tao Q, Murty VV.

Genes Chromosomes Cancer. 2009 Nov;48(11):983-92. doi: 10.1002/gcc.20703.

15.

Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.

Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF.

Gynecol Oncol. 2009 Sep;114(3):480-5. doi: 10.1016/j.ygyno.2009.05.045. Epub 2009 Jun 27.

16.

GPR30 predicts poor survival for ovarian cancer.

Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER.

Gynecol Oncol. 2009 Sep;114(3):465-71. doi: 10.1016/j.ygyno.2009.05.015. Epub 2009 Jun 6.

17.

Novel chemotherapy approaches for cervical cancer.

Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C.

Cancer. 2009 Jul 15;115(14):3166-80. doi: 10.1002/cncr.24364. Review.

18.

Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha.

Scotto L, Narayan G, Nandula SV, Subramaniyam S, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M, Schneider A, Arias-Pulido H, Murty VV.

Mol Cancer. 2008 Jun 17;7:58. doi: 10.1186/1476-4598-7-58.

19.

Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression.

Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, Schneider A, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M, Murty VV.

Genes Chromosomes Cancer. 2008 Sep;47(9):755-65. doi: 10.1002/gcc.20577.

PMID:
18506748
20.

Absence of epidermal growth factor receptor mutations in cervical cancer.

Arias-Pulido H, Joste N, Chavez A, Muller CY, Dai D, Smith HO, Verschraegen CF.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):749-54. Epub 2007 Oct 19.

PMID:
17949425
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk